OTCMKTS:ROSGQ

Rosetta Genomics Competitors

$0.07
+0.00 (+3.85 %)
(As of 04/9/2021 08:27 PM ET)
Add
Compare
Today's Range
$0.07
Now: $0.07
$0.07
50-Day Range
$0.07
MA: $0.11
$0.15
52-Week Range
$0.00
Now: $0.07
$0.39
Volume100 shs
Average Volume79,633 shs
Market Capitalization$123,525.00
P/E RatioN/A
Dividend YieldN/A
Beta6.39

Competitors

Rosetta Genomics (OTCMKTS:ROSGQ) Vs. TRPXD, BSPM, HSTC, EPRSQ, PFSCF, and WDBG

Should you be buying ROSGQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Rosetta Genomics, including Therapix Biosciences (TRPXD), Biostar Pharmaceuticals (BSPM), HST Global (HSTC), EPIRUS Biopharmaceuticals (EPRSQ), ProMetic Life Sciences (PFSCF), and Woodbrook Group (WDBG).

Therapix Biosciences (OTCMKTS:TRPXD) and Rosetta Genomics (OTCMKTS:ROSGQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Institutional and Insider Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Therapix Biosciences and Rosetta Genomics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Therapix Biosciences0000N/A
Rosetta Genomics0000N/A

Profitability

This table compares Therapix Biosciences and Rosetta Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Therapix BiosciencesN/AN/AN/A
Rosetta GenomicsN/AN/AN/A

Valuation and Earnings

This table compares Therapix Biosciences and Rosetta Genomics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A
Rosetta GenomicsN/AN/AN/AN/AN/A

Summary

Therapix Biosciences beats Rosetta Genomics on 1 of the 1 factors compared between the two stocks.

Rosetta Genomics (OTCMKTS:ROSGQ) and Biostar Pharmaceuticals (OTCMKTS:BSPM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Earnings and Valuation

This table compares Rosetta Genomics and Biostar Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rosetta GenomicsN/AN/AN/AN/AN/A
Biostar PharmaceuticalsN/AN/AN/AN/AN/A

Volatility and Risk

Rosetta Genomics has a beta of 6.39, meaning that its share price is 539% more volatile than the S&P 500. Comparatively, Biostar Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Rosetta Genomics and Biostar Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rosetta Genomics0000N/A
Biostar Pharmaceuticals0000N/A

Profitability

This table compares Rosetta Genomics and Biostar Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rosetta GenomicsN/AN/AN/A
Biostar PharmaceuticalsN/AN/AN/A

Summary

Rosetta Genomics beats Biostar Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Rosetta Genomics (OTCMKTS:ROSGQ) and HST Global (OTCMKTS:HSTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Valuation and Earnings

This table compares Rosetta Genomics and HST Global's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rosetta GenomicsN/AN/AN/AN/AN/A
HST GlobalN/AN/A$430,000.00N/AN/A

Volatility & Risk

Rosetta Genomics has a beta of 6.39, meaning that its share price is 539% more volatile than the S&P 500. Comparatively, HST Global has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Rosetta Genomics and HST Global, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rosetta Genomics0000N/A
HST Global0000N/A

Profitability

This table compares Rosetta Genomics and HST Global's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rosetta GenomicsN/AN/AN/A
HST GlobalN/A-1,715.09%-13,300.29%

Summary

Rosetta Genomics beats HST Global on 3 of the 3 factors compared between the two stocks.

Rosetta Genomics (OTCMKTS:ROSGQ) and EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Valuation and Earnings

This table compares Rosetta Genomics and EPIRUS Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rosetta GenomicsN/AN/AN/AN/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A

Volatility & Risk

Rosetta Genomics has a beta of 6.39, meaning that its share price is 539% more volatile than the S&P 500. Comparatively, EPIRUS Biopharmaceuticals has a beta of 6.03, meaning that its share price is 503% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Rosetta Genomics and EPIRUS Biopharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rosetta Genomics0000N/A
EPIRUS Biopharmaceuticals0000N/A

Profitability

This table compares Rosetta Genomics and EPIRUS Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rosetta GenomicsN/AN/AN/A
EPIRUS BiopharmaceuticalsN/AN/AN/A

Summary

Rosetta Genomics beats EPIRUS Biopharmaceuticals on 1 of the 1 factors compared between the two stocks.

Rosetta Genomics (OTCMKTS:ROSGQ) and ProMetic Life Sciences (OTCMKTS:PFSCF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Risk & Volatility

Rosetta Genomics has a beta of 6.39, indicating that its stock price is 539% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500.

Valuation and Earnings

This table compares Rosetta Genomics and ProMetic Life Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rosetta GenomicsN/AN/AN/AN/AN/A
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A

Rosetta Genomics has higher earnings, but lower revenue than ProMetic Life Sciences.

Analyst Ratings

This is a summary of current ratings for Rosetta Genomics and ProMetic Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rosetta Genomics0000N/A
ProMetic Life Sciences0000N/A

Profitability

This table compares Rosetta Genomics and ProMetic Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rosetta GenomicsN/AN/AN/A
ProMetic Life Sciences-894.02%-3,350.55%-67.76%

Institutional & Insider Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Rosetta Genomics beats ProMetic Life Sciences on 4 of the 6 factors compared between the two stocks.

Rosetta Genomics (OTCMKTS:ROSGQ) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Volatility and Risk

Rosetta Genomics has a beta of 6.39, meaning that its stock price is 539% more volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, meaning that its stock price is 324% less volatile than the S&P 500.

Valuation & Earnings

This table compares Rosetta Genomics and Woodbrook Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rosetta GenomicsN/AN/AN/AN/AN/A
Woodbrook GroupN/AN/AN/AN/AN/A

Profitability

This table compares Rosetta Genomics and Woodbrook Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rosetta GenomicsN/AN/AN/A
Woodbrook GroupN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Rosetta Genomics and Woodbrook Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rosetta Genomics0000N/A
Woodbrook Group0000N/A

Summary

Rosetta Genomics beats Woodbrook Group on 1 of the 1 factors compared between the two stocks.


Rosetta Genomics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRPXD
Therapix Biosciences
0.0$5.98+51.8%$454,000.00N/A0.00Gap Up
BSPM
Biostar Pharmaceuticals
0.0$0.17+12.1%$436,000.00N/A0.00Gap Up
HSTC
HST Global
0.8$0.07+108.3%$378,000.00N/A0.00High Trading Volume
Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02+25.3%$366,000.00N/A0.00Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$1.48+14.2%$207,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02+30.0%$118,000.00$20,000.000.00Gap Down
PZRXQ
PhaseRx
0.2$0.01+21.7%$108,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01+26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00+150.0%$81,000.00N/A0.00Gap Up
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02+1.6%$9,000.00$110,000.000.00
Acusphere logo
ACUS
Acusphere
0.0$0.03+1.8%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.09+8.1%$0.00N/A0.00High Trading Volume
Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50+158.7%$0.00N/A0.00Gap Up
ARYX
ARYx Therapeutics
0.0$0.02+27.3%$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01+14.8%$0.00N/A0.00Gap Up
CBPI
China Botanic Pharmaceutical
0.0$0.07+0.0%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01+0.0%$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.49+50.8%$0.00$9.93 million8.13Gap Down
DDXSQ
Diadexus
0.0$0.00+0.0%$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04+14.3%$0.00N/A0.00Gap Down
FTCY
Global Future City
0.5$0.05+1.8%$0.00N/A0.00High Trading Volume
GLSI
Greenwich LifeSciences
1.7$53.60+5.8%$0.00N/A0.00High Trading Volume
Gap Down
HRBR
Harbor Diversified
0.0$1.12+4.5%$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00+0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00+33.3%$0.00N/A0.00High Trading Volume
Gap Down
MBVXQ
MabVax Therapeutics
0.0$0.02+8.7%$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.05+5.8%$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00+41.7%$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.07+8.3%$0.00N/A0.00Gap Down
SGTI
Shengtai Pharmaceutical
0.2$0.03+0.0%$0.00N/A0.00Gap Up
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00+100.0%$0.00N/A0.00Gap Down
SUWN
Sunwin Stevia International
0.5$0.05+14.2%$0.00$26.09 million0.00
SEGI
Sycamore Entertainment Group
0.3$0.03+3.8%$0.00N/A0.00Gap Down
SYNI
Synvista Therapeutics
0.0$0.00+0.0%$0.00N/A0.00
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.07+9.3%$0.00N/A0.00Gap Down
TPIY
Tianyin Pharmaceutical
0.6$0.00+0.0%$0.00N/A0.00High Trading Volume
TBET
Tibet Pharmaceuticals
0.0$0.02+5.3%$0.00N/A0.00Gap Up
VOQP
VioQuest Pharmaceuticals
0.0$0.01+24.3%$0.00N/A0.00Gap Down
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.